NASDAQ:SLNO Soleno Therapeutics (SLNO) Stock Price, News & Analysis → Could this Tiny Biotech End Disease Forever? (From Behind the Markets) (Ad) Free SLNO Stock Alerts $46.26 -0.54 (-1.15%) (As of 04:28 PM ET) Add Compare Share Share Today's Range$44.02▼$46.4650-Day Range$37.14▼$50.5052-Week Range$3.69▼$53.82Volume427,837 shsAverage Volume360,240 shsMarket Capitalization$1.55 billionP/E RatioN/ADividend YieldN/APrice Target$55.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Soleno Therapeutics alerts: Email Address Soleno Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside23.2% Upside$55.60 Price TargetShort InterestBearish15.71% of Float Sold ShortDividend StrengthN/ASustainability-0.55Upright™ Environmental ScoreNews Sentiment0.43Based on 8 Articles This WeekInsider TradingSelling Shares$36.94 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.23) to ($0.92) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.43 out of 5 starsMedical Sector278th out of 905 stocksElectromedical Equipment Industry5th out of 19 stocks 2.5 Analyst's Opinion Consensus RatingSoleno Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSoleno Therapeutics has received no research coverage in the past 90 days.Read more about Soleno Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted15.71% of the float of Soleno Therapeutics has been sold short.Short Interest Ratio / Days to CoverSoleno Therapeutics has a short interest ratio ("days to cover") of 10.2, which indicates bearish sentiment.Change versus previous monthShort interest in Soleno Therapeutics has recently increased by 12.32%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSoleno Therapeutics does not currently pay a dividend.Dividend GrowthSoleno Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSoleno Therapeutics has received a 73.45% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for genetic diseases" and "Basic medical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Soleno Therapeutics is -0.55. Previous Next 1.9 News and Social Media Coverage News SentimentSoleno Therapeutics has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Soleno Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for SLNO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Soleno Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Soleno Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $36,940,260.00 in company stock.Percentage Held by Insiders28.80% of the stock of Soleno Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.42% of the stock of Soleno Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Soleno Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Soleno Therapeutics are expected to grow in the coming year, from ($1.23) to ($0.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Soleno Therapeutics is -15.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Soleno Therapeutics is -15.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSoleno Therapeutics has a P/B Ratio of 8.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Soleno Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaElon Musk Secret Crypto Plot ExposedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Soleno Therapeutics Stock (NASDAQ:SLNO)Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.Read More SLNO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SLNO Stock News HeadlinesMay 2, 2024 | insidertrades.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Major Shareholder Vivo Opportunity, Llc Sells 750,000 SharesMay 8, 2024 | finance.yahoo.comWhile institutions invested in Soleno Therapeutics, Inc. (NASDAQ:SLNO) benefited from last week's 4.8% gain, private equity firms stood to gain the mostMay 8, 2024 | InvestorPlace (Ad)The new financial threat that could wipe out millions…During the Internet boom, companies like Pets.com were supposed to be promising investments riding the wave of a new tech boom. But then they were gone within a blink of an eye. One of the most successful investors in history just stepped forward to say the same thing is about to happen to AI stocks.May 5, 2024 | americanbankingnews.comSoleno Therapeutics (NASDAQ:SLNO) Shares Gap Down to $49.23May 3, 2024 | americanbankingnews.comVivo Opportunity, Llc Sells 750,000 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) StockMay 3, 2024 | nasdaq.comSoleno Therapeutics Prices Public Offering Of 3 Mln Shares At $46/shr; Stock Down In After-hoursMay 2, 2024 | globenewswire.comSoleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common StockMay 2, 2024 | globenewswire.comSoleno Therapeutics Announces Proposed Public Offering of Common StockMay 8, 2024 | InvestorPlace (Ad)The new financial threat that could wipe out millions…During the Internet boom, companies like Pets.com were supposed to be promising investments riding the wave of a new tech boom. But then they were gone within a blink of an eye. One of the most successful investors in history just stepped forward to say the same thing is about to happen to AI stocks.April 30, 2024 | globenewswire.comSoleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi SyndromeApril 29, 2024 | marketwatch.comSoleno Therapeutics Gets Breakthrough Therapy Designation for Diazoxide CholineApril 29, 2024 | marketwatch.comSoleno Therapeutics Shares Rise 37% After Breakthrough Designation for Diazoxide CholineApril 29, 2024 | seekingalpha.comSoleno: Mid-2024 NDA Filing For PWS Treatment Is A Major Catalyst To WatchApril 29, 2024 | fool.comWhy Soleno Therapeutics Stock Is Skyrocketing TodayApril 29, 2024 | globenewswire.comSoleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)April 19, 2024 | globenewswire.comSoleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 5, 2024 | investing.comSoleno Therapeutics CEO sells over $780k in company stockApril 4, 2024 | finance.yahoo.comInsider Sell: CFO James Mackaness Sells 5,175 Shares of Soleno Therapeutics Inc (SLNO)April 4, 2024 | finance.yahoo.comCEO Bhatnagar Anish Sells 18,980 Shares of Soleno Therapeutics Inc (SLNO)March 16, 2024 | finance.yahoo.comSLNO Apr 2024 40.000 putMarch 16, 2024 | finance.yahoo.comSLNO Apr 2024 35.000 putMarch 11, 2024 | bizjournals.comConstruction of Soleno's $22M pipe factory in Saratoga underwayMarch 11, 2024 | finance.yahoo.comWe're Not Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash BurnMarch 8, 2024 | globenewswire.comSoleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 8, 2024 | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on Soleno Therapeutics (SLNO)March 7, 2024 | investorplace.comSLNO Stock Earnings: Soleno Therapeutics Misses EPS for Q4 2023March 6, 2024 | globenewswire.comSoleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial ResultsSee More Headlines Receive SLNO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Soleno Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/06/2024Today5/08/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical equipment Sub-IndustryN/A Current SymbolNASDAQ:SLNO CUSIPN/A CIK1484565 Webwww.soleno.life Phone(650) 213-8444Fax650-213-8383Employees33Year FoundedN/APrice Target and Rating Average Stock Price Target$55.60 High Stock Price Target$93.00 Low Stock Price Target$35.00 Potential Upside/Downside+21.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-38,990,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-79.65% Return on Assets-52.92% Debt Debt-to-Equity RatioN/A Current Ratio14.89 Quick Ratio14.89 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.16 per share Price / Book8.89Miscellaneous Outstanding Shares33,410,000Free Float23,789,000Market Cap$1.53 billion OptionableOptionable Beta-1.51 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Anish Bhatnagar M.D. (Age 54)President, CEO, COO & Director Comp: $835.2kMr. James H. MacKaness (Age 60)Chief Financial Officer Comp: $539kMs. Patricia C. Hirano (Age 58)Vice President of Regulatory Affairs Comp: $423.8kKey CompetitorsInModeNASDAQ:INMDCONMEDNYSE:CNMDBioLife SolutionsNASDAQ:BLFSRhythm PharmaceuticalsNASDAQ:RYTMLarimar TherapeuticsNASDAQ:LRMRView All CompetitorsInsiders & InstitutionsSwiss National BankBought 7,300 shares on 5/7/2024Ownership: 0.090%Sei Investments Co.Bought 2,264 shares on 5/7/2024Ownership: 0.038%Carlyle Group Inc.Bought 1,213,758 shares on 5/3/2024Ownership: 12.187%Vivo Opportunity, LlcSold 750,000 sharesTotal: $35.85 M ($47.80/share)Allspring Global Investments Holdings LLCBought 103,839 shares on 4/18/2024Ownership: 0.311%View All Insider TransactionsView All Institutional Transactions SLNO Stock Analysis - Frequently Asked Questions Should I buy or sell Soleno Therapeutics stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Soleno Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SLNO shares. View SLNO analyst ratings or view top-rated stocks. What is Soleno Therapeutics' stock price target for 2024? 5 analysts have issued 1-year target prices for Soleno Therapeutics' stock. Their SLNO share price targets range from $35.00 to $93.00. On average, they anticipate the company's share price to reach $55.60 in the next twelve months. This suggests a possible upside of 23.2% from the stock's current price. View analysts price targets for SLNO or view top-rated stocks among Wall Street analysts. How have SLNO shares performed in 2024? Soleno Therapeutics' stock was trading at $40.25 at the beginning of 2024. Since then, SLNO stock has increased by 12.1% and is now trading at $45.14. View the best growth stocks for 2024 here. When is Soleno Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our SLNO earnings forecast. How were Soleno Therapeutics' earnings last quarter? Soleno Therapeutics, Inc. (NASDAQ:SLNO) announced its earnings results on Wednesday, March, 6th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by $0.02. What ETFs hold Soleno Therapeutics' stock? ETFs with the largest weight of Soleno Therapeutics (NASDAQ:SLNO) stock in their portfolio include Invesco DWA SmallCap Momentum ETF (DWAS), Virtus LifeSci Biotech Clinical Trials ETF (BBC), ALPS Medical Breakthroughs ETF (SBIO) and Tema Cardiovascular and Metabolics ETF (HRTS). When did Soleno Therapeutics' stock split? Shares of Soleno Therapeutics reverse split before market open on Friday, August 26th 2022. The 1-15 reverse split was announced on Friday, August 26th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Soleno Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Soleno Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), OPKO Health (OPK), ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Miragen Therapeutics (MGEN), Vaxart (VXRT), Dynavax Technologies (DVAX) and TherapeuticsMD (TXMD). Who are Soleno Therapeutics' major shareholders? Soleno Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Carlyle Group Inc. (12.19%), Allspring Global Investments Holdings LLC (0.31%), Swiss National Bank (0.09%), Sei Investments Co. (0.04%) and Cannon Global Investment Management LLC (0.04%). Insiders that own company stock include Bhatnagar Anish, Jack W Schuler, James H Mackaness, Kristen Yen, Perceptive Advisors Llc and Vivo Opportunity, Llc. View institutional ownership trends. How do I buy shares of Soleno Therapeutics? Shares of SLNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SLNO) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyAI “wealth window” is closing June 25thParadigm PressGold Set to EXPLODE!Gold Safe ExchangeShocking: One AI startup's revenue could surge 4,735%Manward PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsCharles Payne Demystifies OptionsUnstoppable ProsperityThe AI Stock that’s Disrupting Every IndustryStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soleno Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
